Measurements of immune responses for establishing correlates of vaccine protection against HIV

AIDS Research and Human Retroviruses

Volumn 28, Issue 7, 2012, Pages 641-648

  Burgers, Wendy A ^a   Manrique, Amapola ^b   Masopust, David ^c   McKinnon, Lyle R ^d,e   Reynolds, Matthew R ^f   Rolland, Morgane ^g   Blish, Catherine ^h   Chege, Gerald K ^a   Curran, Rhonda ⁱ   Fischer, William ^j   Herrera, Carolina ^k   Sather, D Noah ^l  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b Global HIV Vaccine Enterprise   (United States)

^c UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF TORONTO   (Canada)

^e UNIVERSITY OF NAIROBI   (Kenya)

^f UNIVERSITY OF WISCONSIN MADISON   (United States)

^g US Military HIV Research Program   (United States)

^h STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ UNIVERSITY OF ULSTER   (United Kingdom)

^j LOS ALAMOS NATIONAL LABORATORY   (United States)

^k IMPERIAL COLLEGE LONDON   (United Kingdom)

^l SEATTLE BIOMEDICAL RESEARCH INSTITUTE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALVAC HIV; HERPESVIRUS VECTOR; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; UNCLASSIFIED DRUG;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY DEPENDENT CELLULAR VIRAL INHIBITION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CLINICAL RESEARCH; CONFERENCE PAPER; DRUG EFFICACY; EXPRESSION VECTOR; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOLOGICAL MEMORY; INNATE IMMUNITY; MEDICAL INFORMATION; METHODOLOGY; NONHUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTECTION; VACCINATION; VIRUS INHIBITION;

AIDS VACCINES; FEMALE; GENETIC VECTORS; HIV SEROPOSITIVITY; HIV-1; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, MUCOSAL; IMMUNOLOGIC MEMORY; MALE; T-LYMPHOCYTES; VACCINES, SYNTHETIC;

EID: 84863191097     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2011.0239     Document Type: Conference Paper

References (46)

1. Lambert PH, Liu M, and Siegrist CA: Can successful vaccines teach us how to induce efficient protective immune responses? Nat Med 2005;11:S54-62. (Pubitemid 40562304)
2. Plotkin SA: Correlates of protection induced by vaccination. Clin Vaccine Immunol 2010;17:1055-1065.
3. Plotkin SA: Vaccines: Correlates of vaccine-induced immunity. Clin Infect Dis 2008;47:401-409.
4. Moxon ER, Das P, Greenwood B, et al.: A call to action for the new decade of vaccines. Lancet 2011;378:298-302.
5. Plotkin SA: Vaccines: Past, present and future. Nat Med 2005;11:S5-11. (Pubitemid 40562297)
6. Amanna IJ, Messaoudi I, and Slifka MK: Protective immunity following vaccination: How is it defined? Hum Vaccine 2008;4:316-319.
7. Hammarlund E, Lewis MW, Hansen SG, et al.: Duration of antiviral immunity after smallpox vaccination. Nat Med 2003;9:1131-1137. (Pubitemid 37173696)
8. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, et al.: Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009;361:2209-2220.
9. Buchbinder SP, Mehrotra DV, Duerr A, et al.: Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): A double-blind, randomised, placebocontrolled, test-of-concept trial. Lancet 2008;372:1881-1893.
10. Rolland M, Tovanabutra S, deCamp AC, et al.: Genetic impact of vaccination on breakthrough HIV-1 sequences from the STEP trial. Nat Med 2011;17:366-371.
11. McElrath MJ, De Rosa SC, Moodie Z, et al.: HIV-1 vaccineinduced immunity in the test-of-concept Step Study: A casecohort analysis. Lancet 2008;372:1894-1905.
12. Gray GE, Allen M, Moodie Z, et al.: Safety and efficacy of the HVTN 503/Phambili study of a clade-B-based HIV-1 vaccine in South Africa: A double-blind, randomised, placebo-controlled test-of-conceptphase 2b study. Lancet Infect Dis 2011;11:507-515.
13. Koup RA, Safrit JT, Cao Y, et al.: Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol 1994;68:4650-4655. (Pubitemid 24183063)
14. Borrow P, Lewicki H, Hahn BH, Shaw GM, and Oldstone MB: Virus-specific CD8 + cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J Virol 1994;68:6103-6110. (Pubitemid 24258634)
15. Watkins DI, Burton DR, Kallas EG, Moore JP, and Koff WC: Nonhuman primate models and the failure of the Merck HIV-1 vaccine in humans. Nat Med 2008;14:617-621. (Pubitemid 351809543)
16. Hansen SG, Vieville C, Whizin N, et al.: Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challenge. Nat Med 2009;15:293-299.
17. Keele BF, Li H, Learn GH, et al.: Low-dose rectal inoculation of rhesus macaques by SIVsmE660 or SIVmac251 racapitulates human mucosal infection by HIV-1. J Exp Med 2009; 206:1117-134.
18. Casazza JP, Brenchley JM, Hill BJ, et al.: Autocrine production of beta-chemokines protects CMV-specific CD4 T cells from HIV infection. PLoS Pathog 2009;5:e1000646.
19. Haynes BF and Shattock RJ: Critical issues in mucosal immunity for HIV-1 vaccine development. J Allergy Clin Immunol 2008;122:3-9; quiz 10-1.
20. Critchfield JW, Young DH, Hayes TL, et al.: Magnitude and complexity of rectal mucosa HIV-1-specific CD8+ T-cell responses during chronic infection reflect clinical status. PLoS One 2008;3:e3577.
21. Shibata R, Igarashi T, Haigwood N, et al.: Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys. Nat Med 1999;5:204-210. (Pubitemid 29068528)
22. Baba TW, Liska V, Hofmann-Lehmann R, et al.: Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection. Nat Med 2000;6:200-206. (Pubitemid 30082366)
23. Mascola JR, Stiegler G, VanCott TC, et al.: Protection of macaques against vaginal transmission of a pathogenic HIV- 1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat Med 2000;6:207-210. (Pubitemid 30082367)
24. Florese RH, Demberg T, Xiao P, et al.: Contribution of nonneutralizing vaccine-elicited antibody activities to improved protective efficacy in rhesus macaques immunized with Tat/Env compared with multigenic vaccines. J Immunol 2009;182:3718-3727.
25. Hessell AJ, Hangartner L, Hunter M, et al.: Fc receptor but not complement binding is important in antibody protection against HIV. Nature 2007;449:101-104. (Pubitemid 47373775)
26. Xiao P, Zhao J, Patterson LJ, et al.: Multiple vaccine-elicited nonneutralizing antienvelope antibody activities contribute to protective efficacy by reducing both acute and chronic viremia following simian/human immunodeficiency virus SHIV89.6P challenge in rhesus macaques. J Virol 2010;84: 7161-7173.
27. Goepfert PA, Tomaras GD, Horton H, et al.: Durable HIV-1 antibody and T-cell responses elicited by an adjuvanted multi-protein recombinant vaccine in uninfected human volunteers. Vaccine 2007;25:510-518. (Pubitemid 44856093)
28. Evans TG, Frey S, Israel H, et al.: Long-term memory B-cell responses in recipients of candidate human immunodeficiency virus type 1 vaccines. Vaccine 2004;22:2626-2630. (Pubitemid 38757366)
29. Vaine M, Wang S, Liu Q, et al.: Profiles of human serum antibody responses elicited by three leading HIV vaccines focusing on the induction of Env-specific antibodies. PLoS One 2010;5:e13916.
30. Moir S and Fauci AS: B cells in HIV infection and disease. Nat Rev Immunol 2009;9:235-245.
31. Poland JD, Calisher CH, Monath TP, Downs WG, and Murphy K: Persistence of neutralizing antibody 30-35 years after immunization with 17D yellow fever vaccine. Bull World Health Organ 1981;59:895-900. (Pubitemid 12155776)
32. Wu Q, Zhuang GH, Wang XL, Wang LR, Li N, and Zhang M: Antibody levels and immune memory 23 years after primary plasma-derived hepatitis B vaccination: Results of a randomized placebo-controlled trial cohort from China where endemicity is high. Vaccine 2011;29:2302-2307.
33. Koup RA, Graham BS, and Douek DC: The quest for a T cellbased immune correlate of protection against HIV: A story of trials and errors. Nat Rev Immunol 2011;11:65-70.
34. Corey L, Nabel GJ, Dieffenbach C, et al.: HIV-1 vaccines and adaptive trial designs. Sci Transl Med 2011;3:79ps13.
35. Fischer W, Perkins S, Theiler J, et al.: Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants. Nat Med 2007;13:100-106. (Pubitemid 46067393)
36. Barouch DH, OBrien KL, Simmons NL, et al.: Mosaic HIV-1 vaccines expand the breadth and depth of cellular immune responses in rhesus monkeys. Nat Med 2010;16: 319-323.
37. Santra S, Liao HX, Zhang R, et al.: Mosaic vaccines elicit CD8 + T lymphocyte responses that confer enhanced immune coverage of diverse HIV strains in monkeys. Nat Med 2010;16:324-328.
38. Buchbinder SP and Liu A: Pre-exposure prophylaxis and the promise of combination prevention approaches. AIDS Behav 2011;15(Suppl 1):S72-9.
39. Veronese F, Anton P, Fletcher CV, et al.: Implications of HIV PrEP trials results. AIDS Res Hum Retroviruses 2011;27:81-90.
40. Bailey RC, Moses S, Parker CB, et al.: Male circumcision for HIV prevention in young men in Kisumu, Kenya: A randomised controlled trial. Lancet 2007;369:643-656. (Pubitemid 46281312)
41. Gray RH, Kigozi G, Serwadda D, et al.: Male circumcision for HIV prevention in men in Rakai, Uganda: A randomised trial. Lancet 2007;369:657-666.
42. Auvert B, Taljaard D, Lagarde E, Sobngwi-Tambekou J, Sitta R, and Puren A: Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: The ANRS 1265 Trial. PLoS Med 2005;2:e298.
43. Abdool Karim Q, Abdool Karim SS, Frohlich JA, et al.: Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 2010;329:1168-1174.
44. Grant RM, Lama JR, Anderson PL, et al.: Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 2010;363:2587-2599.
45. Excler JL, Rida W, Priddy F, et al.: AIDS vaccines and preexposure prophylaxis: Is synergy possible? AIDS Res Hum Retroviruses 2011;27:669-680.
46. Gilbert P, Wang M, Wrin T, et al.: Magnitude and breadth of a nonprotective neutralizing antibody response in an efficacy trial of a candidate HIV-1 gp120 vaccine. J Infect Dis 2010;202:595-605.